ImmuPharma (LON:IMM)‘s stock had its “buy” rating reissued by equities research analysts at FinnCap in a research report issued to clients and investors on Thursday, December 21st. They presently have a GBX 237 ($3.21) target price on the stock. FinnCap’s price target would suggest a potential upside of 50.96% from the company’s previous close.
A number of other brokerages have also recently commented on IMM. Northland Securities reissued a “buy” rating and issued a GBX 181 ($2.45) price objective on shares of ImmuPharma in a research note on Thursday, November 2nd. Northland Capital Partners reissued a “buy” rating and issued a GBX 181 ($2.45) price objective on shares of ImmuPharma in a research note on Thursday, September 21st.
ImmuPharma (LON:IMM) opened at GBX 157 ($2.13) on Thursday. The firm has a market cap of $204.38 and a price-to-earnings ratio of -3,925.00. ImmuPharma has a 52 week low of GBX 44 ($0.60) and a 52 week high of GBX 193.74 ($2.63).
ILLEGAL ACTIVITY NOTICE: “ImmuPharma (IMM) Given Buy Rating at FinnCap” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/01/14/immupharma-imm-receives-buy-rating-from-finncap-2-updated-updated.html.
ImmuPharma Company Profile
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.